HARBIN, China, March 30 RenhuangPharmaceuticals, Inc. (Pink Sheets: RHGP) ("Renhuang" or the "Company"), adeveloper, manufacturer and distributor of botanical products,bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announcedthat the Company has been awarded the prestigious High-Technology Enterprisecertificate ("Certificate") by the government of Heilongjiang Province.
The Certificate was issued in accordance with the new 2008 "High-techenterprise management standard" of the National Torch Plan, a programestablished in 1988 by China's Ministry of Science and Technology to encourageinnovation and promote the development of China's high-tech industry. As aCertificate recipient, Renhuang will have access to a series of national andlocal government support programs, including favorable tax treatment,intellectual property protection, and technical support from the central andlocal government.
"Renhuang is honored to once again receive the Certificate, which hashelped to enhance our internal R&D efforts," said Mr. Shaoming Li, theChairman and CEO of Renhuang. "We appreciate the provincial government'srecognition of the Company's scientific approach to new drug development,technological innovations and strong commitment to advancing medical research.Renhuang will continue to focus on leveraging our expertise and uniquetechnologies to drive long-term, sustainable growth."
ABOUT RENHUANG PHARMACEUTICALS, INC.
Renhuang Pharmaceuticals, Inc. is engaged in the development,manufacturing, and distribution of botanical products, bio-pharmaceuticalproducts, and traditional Chinese medicines ("TCM"), in the People's Republicof China. All of the Company's products are produced at its threeGMP-certified production facilities in Ah City, Dongfanghong and Qingyang.The Company distributes its botanical anti-depression and nerve-regulationproducts, biopharmaceutical products, and botanical antibiotic and OTC TCMsthrough its network of over 3,000 distributors and over 70 sales centersacross 24 provinces in China.
Safe Harbor Statement
This press release contains certain statements that may includeforward-looking statements within the meaning of the Private SecuritiesLitigation Reform Act of 1995. Such statements are based upon management'sbeliefs, assumptions and expectations of the Company's future operations andeconomic performance, taking into account the information currently availableto management. These statements are not statements of historical fact.Forward-looking statements involve risks and uncertainties, some of which arenot currently known that may cause actual results, performance or financialcondition to be materially different from the expectations of future results,performance or financial condition expressed or implied in any forward-lookingstatements. These forward-looking statements are based on current plans andexpectations and are subject to a number of uncertainties including, but notlimited to, the Company's ability to achieve its financial guidance, abilityto list its shares on a senior stock exchange, ability to manage expansion ofits operations effectively, competition in the marketing and sales of itsproducts, and other factors detailed in the Company's annual report on Form10-K and other filings with the Securities and Exchange Commission. TheCompany undertakes no obligation to publicly update or revise anyforward-looking statements, whether as a result of new information, futureevents or otherwise. You are cautioned not to unduly rely on suchforward-looking statements when evaluating the information presented herein.For more information, please contact: Renhuang Pharmaceuticals, Inc. Ms. Portia Tan, IR Contact Tel: +86-451-5392-5461 Email: [email protected]
CCG Investor Relations: Ms. Lei Huang, Account Manager Phone: +1-646-833-3417 (New York) Email: [email protected]
Web: http://www.ccgirasia.com Mr. Crocker Coulson, President Phone: +1-646-213-1915 (New York) Email: [email protected]
SOURCE Renhuang Pharmaceuticals, Inc.